There is an urgent societal and medical need for improved drugs and for a more efficient development track for these new products. This includes a reduction in the numbers of animals used in drug development and an improvement in the predictive value of the model systems used in early stage drug testing.

Our BDDD programme brings together researchers who focus their activities on enabling technologies applied in pharmaceutical R&D. We contribute to a better and more efficient development of new drugs and therapeutic concepts by exploring the various fundamental and applied aspects of drug research and development.

We will generate societal and economic value through the innovative drug concepts we study becasue we improve drugs and technologies used in drug development, production, administration and safety assessment. 


Relevant research to an ageing population

On average more than 70% of the drugs used in society are used by the elderly.  Many of the diseases that are the focus of the research in our programme are also age-related.  Cancer, COPD, fibrosis, Parkinsonism and influenza are all diseases that become increasingly problematic in an ageing population. So research on new drugs is by definition highly relevant to the ageing population.

​​​​​​We collaborate with departments such as Oncology, Pulmonology, Surgery, Gastroenterology and Hepatology. Our collaborations are essential and an important aspect of daily research routine:

  • they ensure the translational character of the research
  • and provide us with real-life feedback on our research efforts
  • inspire future research.
  • facilitate full drug development up to market introduction

Our combined efforts increase the societal and economic value of our research.​​​​